NCT04704453.

Study name	Phase II randomized controlled study aiming to evaluate the interest of Qutenza in patients with head and neck cancer in remission and with sequelae neuropathic pain
Methods	Double‐blind, parallel, 2‐arm RCT 9 months
Participants	Unclear pain duration from trial registration Head and neck cancer in remission: absence of clinical or radiological signs of progression at least 3 months after specific treatments Pain of the cervico‐facial sphere persisting for > 3 months after surgical and/or radiotherapy treatment Peripheral neuropathic character of pain objectified to a score ≥ 4/10 on the DN (Douleur Neuropathique) 4 questionnaire Pain whose average intensity over the last 24 hours is assessed on the numerical scale as ≥ 2/10 Target: 130
Interventions	Capsaïcin patch (Qutenza) 8% Amitriptyline flexibly dosed 25‐75 mg
Outcomes	Pain intensity Neuropathic pain symptoms Quality of life AEs
Starting date	28 April 2021
Contact information	Antoine Boden 05 31 15 57 91 boden.antoine@iuct‐oncopole.fr
Notes